Advertisement

Liver Transplant for Hepatocellular Carcinoma

  • Thomas A. Aloia
  • A. Osama Gaber
  • R. Mark Ghobrial
Chapter

Abstract

Currently, liver transplantation stands as the best treatment modality for early-stage hepatocellular carcinoma in patients with decompensated cirrhosis, giving patients the opportunity to be free from the potentially lethal complications from both cancer and their advanced underlying liver disease. Following a historical period characterized by high hepatocellular carcinoma recurrence rates following transplantation of patients with advanced stage disease, introduction of the “Milan criteria” encouraged a focus on early stage hepatocellular carcinoma and improved patient and oncologic outcomes were achieved. Data are emerging that patients with tumor size and tumor number slightly in excess of those proposed in the Conventional Milan Criteria share equivalent survivals with traditional early stage patients and should also be considered for liver transplantation. In settings where the number of patients with hepatocellular carcinoma and indications for transplant exceed the number of cadaveric liver allografts, alternative strategies are requisite. These include more liberal use of liver resection, interventional and systemic treatments, and living-related liver transplantation. The field has seen tremendous development and is now under considerable pressure due to epidemic rates of hepatocellular carcinoma in both hepatitis and fatty liver disease-induced cirrhotics. In this setting, multiple controversies in the field require resolution by clinical trial and/or consensus.

Keywords

Liver cancer Liver transplantation Immunosuppression Outcomes Prognostic factors 

References

  1. 1.
    Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR (1963) Homotransplantation of the liver in humans. Surg Gynecol Obstet 117:659–676PubMedGoogle Scholar
  2. 2.
    Starzl TE (1992) The puzzle people: memoirs of a transplant surgeon. University of Pittsburg Press, Pittsburgh, PAGoogle Scholar
  3. 3.
    Starzl TE, Iwatsuki S, Van Thiel DH et al (1982) Evolution of liver transplantation. Hepatology 2:614–636PubMedGoogle Scholar
  4. 4.
    Iwatsuki S, Gordon RD, Shaw BW, Jr, Starzl TE (1985) Role of liver transplantation in cancer therapy. Ann Surg 202:401–407CrossRefPubMedGoogle Scholar
  5. 5.
    Klintmalm GB, Stone MJ (1990) Liver transplantation for malignancy. Transpl Rev 4:52–58Google Scholar
  6. 6.
    Ringe B, Pichlmayr R, Wittekind C, Tusch G (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15:270–285CrossRefPubMedGoogle Scholar
  7. 7.
    Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699CrossRefPubMedGoogle Scholar
  8. 8.
    Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ (2003) The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21:4329–4335CrossRefPubMedGoogle Scholar
  9. 9.
    Sala M, Varela M, Bruix J (2004) Selection of candidates with HCC for transplantation in the MELD era. Liver Transpl 10(10 Suppl 2):S4–S9CrossRefPubMedGoogle Scholar
  10. 10.
    Yao FY, Ferrell L, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403CrossRefPubMedGoogle Scholar
  11. 11.
    Shetty K, Timmins K, Brensinger C et al (2004) Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 10:911–918CrossRefPubMedGoogle Scholar
  12. 12.
    Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ (2001) Liver transplantation for hepatocellular carcinoma. Ann Surg 233:652–659CrossRefPubMedGoogle Scholar
  13. 13.
    Jonas S, Bechstein WO, Steinmuller T et al (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33:1080–1086CrossRefPubMedGoogle Scholar
  14. 14.
    Bruix J, Fuster J, Llovet JM (2003) Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 9:700–702CrossRefPubMedGoogle Scholar
  15. 15.
    McGlynn KA, Tarone RE, El-Serag HB (2006) A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15:1198–1203CrossRefPubMedGoogle Scholar
  16. 16.
    El-Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36(5 Suppl 1):S74–S83CrossRefPubMedGoogle Scholar
  17. 17.
    Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRefPubMedGoogle Scholar
  18. 18.
    Freeman RB, Jr, Wiesner RH, Harper A et al (2002) The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8:851–858CrossRefPubMedGoogle Scholar
  19. 19.
    Ioannou GN, Perkins JD, Carithers RL, Jr (2008) Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 134:1342–1351CrossRefPubMedGoogle Scholar
  20. 20.
    Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2007) Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 245:51–58CrossRefPubMedGoogle Scholar
  21. 21.
    Bigourdan JM, Jaeck D, Meyer N et al (2003) Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 9:513–520CrossRefPubMedGoogle Scholar
  22. 22.
    Duffy JP, Vardanian A, Benjamin E et al (2007) Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246:502–511CrossRefPubMedGoogle Scholar
  23. 23.
    Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104CrossRefPubMedGoogle Scholar
  24. 24.
    Louha M, Nicolet J, Zylberberg H et al (1999) Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology 29:879–882CrossRefPubMedGoogle Scholar
  25. 25.
    Stigliano R, Burroughs AK (2005) Should we biopsy each liver mass suspicious for HCC before liver transplantation?–no, please don’t. J Hepatol 43:563–568CrossRefPubMedGoogle Scholar
  26. 26.
    Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10(2 Suppl 1):S115–S120CrossRefPubMedGoogle Scholar
  27. 27.
    Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. JNCI 100:698–711PubMedGoogle Scholar
  28. 28.
    Kaihara S, Kiuchi T, Ueda M et al (2003) Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 75(3 Suppl):S37–S40CrossRefPubMedGoogle Scholar
  29. 29.
    Ravaioli M, Grazi GL, Piscaglia F et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8:2547–2557CrossRefPubMedGoogle Scholar
  30. 30.
    Herrero JI, Sangro B, Quiroga J et al (2001) Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 7:631–636CrossRefPubMedGoogle Scholar
  31. 31.
    Yao FY, Kerlan RK, Jr, Hirose R et al (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48:819–827CrossRefPubMedGoogle Scholar
  32. 32.
    Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al (2006) Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12:1761–1769CrossRefPubMedGoogle Scholar
  33. 33.
    Ravaioli M, Ercolani G, Cescon M et al (2004) Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 10:1195–1202CrossRefPubMedGoogle Scholar
  34. 34.
    Yang SH, Suh KS, Lee HW et al (2007) A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 141:598–609CrossRefPubMedGoogle Scholar
  35. 35.
    Marsh JW, Dvorchik I, Subotin M et al (1997) The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 26:444–450CrossRefPubMedGoogle Scholar
  36. 36.
    Schwartz M (2004) Liver transplantation for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S268–S276CrossRefPubMedGoogle Scholar
  37. 37.
    Fisher RA, Maluf D, Cotterell AH et al (2004) Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 18:502–512CrossRefPubMedGoogle Scholar
  38. 38.
    Cillo U, Vitale A, Bassanello M et al (2004) Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239:150–159CrossRefPubMedGoogle Scholar
  39. 39.
    Todo S, Furukawa H (2004) Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240:451–461CrossRefPubMedGoogle Scholar
  40. 40.
    Yao FY, Bass NM, Nikolai B et al (2003) A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 9:684–692CrossRefPubMedGoogle Scholar
  41. 41.
    Maddala YK, Stadheim L, Andrews JC et al (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10:449–455CrossRefPubMedGoogle Scholar
  42. 42.
    Porrett PM, Peterman H, Rosen M et al (2006) Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 12:665–673CrossRefPubMedGoogle Scholar
  43. 43.
    Oldhafer KJ, Chavan A, Fruhauf NR et al (1998) Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 29:953–959CrossRefPubMedGoogle Scholar
  44. 44.
    Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al (2005) Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 11:767–775CrossRefPubMedGoogle Scholar
  45. 45.
    Roayaie S, Frischer JS, Emre SH et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533–539CrossRefPubMedGoogle Scholar
  46. 46.
    Graziadei IW, Sandmueller H, Waldenberger P et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557–563CrossRefPubMedGoogle Scholar
  47. 47.
    Hayashi PH, Ludkowski M, Forman LM et al (2004) Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transpl 4:782–787CrossRefGoogle Scholar
  48. 48.
    Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMedGoogle Scholar
  49. 49.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMedGoogle Scholar
  50. 50.
    Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6:2644–2650CrossRefPubMedGoogle Scholar
  51. 51.
    Aloia TA, Fahy BN (2008) A decision analysis model predicts the optimal treatment pathway for patients with colorectal cancer and resectable synchronous liver metastases. Clin Colorectal Cancer 7:197–201CrossRefPubMedGoogle Scholar
  52. 52.
    Lu DS, Yu NC, Raman SS et al (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41:1130–1137CrossRefPubMedGoogle Scholar
  53. 53.
    Lu DS, Yu NC, Raman SS et al (2005) Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234:954–960CrossRefPubMedGoogle Scholar
  54. 54.
    Mazzaferro V, Battiston C, Perrone S et al (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240:900–909CrossRefPubMedGoogle Scholar
  55. 55.
    Salem R, Thurston KG (2006) Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 17:1571–1593CrossRefPubMedGoogle Scholar
  56. 56.
    Kulik LM, Atassi B, van Holsbeeck L et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586CrossRefPubMedGoogle Scholar
  57. 57.
    Riaz A, Kulik L, Lewandowski RJ et al (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49:1185–1193CrossRefPubMedGoogle Scholar
  58. 58.
    Lo CM, Liu CL, Chan SC et al (2007) A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831–842CrossRefPubMedGoogle Scholar
  59. 59.
    Simonetti RG, Liberati A, Angiolini C, Pagliaro L (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8:117–136CrossRefPubMedGoogle Scholar
  60. 60.
    Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300CrossRefPubMedGoogle Scholar
  61. 61.
    Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390Google Scholar
  62. 62.
    Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327CrossRefPubMedGoogle Scholar
  63. 63.
    Fernandez JA, Robles R, Marin C et al (2003) Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 35:1818–1820CrossRefPubMedGoogle Scholar
  64. 64.
    Leung JY, Zhu AX, Gordon FD et al (2004) Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 10:1343–1354CrossRefPubMedGoogle Scholar
  65. 65.
    Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP (2002) Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8:765–774CrossRefPubMedGoogle Scholar
  66. 66.
    Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35–43CrossRefPubMedGoogle Scholar
  67. 67.
    Majno PE, Adam R, Bismuth H et al (1997) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688–701CrossRefPubMedGoogle Scholar
  68. 68.
    Yao FY, Hirose R, LaBerge JM et al (2005) A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11:1505–1514CrossRefPubMedGoogle Scholar
  69. 69.
    Llovet JM, Schwartz M, Fuster J, Bruix J (2006) Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis 26:248–253CrossRefPubMedGoogle Scholar
  70. 70.
    Belghiti J, Cortes A, Abdalla EK et al (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238:885–893CrossRefPubMedGoogle Scholar
  71. 71.
    Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229:790–800CrossRefPubMedGoogle Scholar
  72. 72.
    Ercolani G, Grazi GL, Ravaioli M et al (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237:536–543CrossRefPubMedGoogle Scholar
  73. 73.
    Adam R, Azoulay D, Castaing D et al (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238:508–519CrossRefPubMedGoogle Scholar
  74. 74.
    Kulik L, Abecassis M (2004) Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S277–S282Google Scholar
  75. 75.
    Fisher RA, Kulik LM, Freise CE et al (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7:1601–1608CrossRefPubMedGoogle Scholar
  76. 76.
    Thuluvath PJ, Yoo HY (2004) Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 10:1263–1238Google Scholar
  77. 77.
    Hwang S, Lee SG, Joh JW, Suh KS, Kim DG (2005) Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 11:1265–1272CrossRefPubMedGoogle Scholar
  78. 78.
    Lo CM, Fan ST, Liu CL, Chan SC, Wong J (2004) The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 10:440–447CrossRefPubMedGoogle Scholar
  79. 79.
    Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A (2001) Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 33:1073–1079CrossRefPubMedGoogle Scholar
  80. 80.
    Zavaglia C, De Carlis L, Alberti AB et al (2005) Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 100:2708–2716CrossRefPubMedGoogle Scholar
  81. 81.
    Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I (2002) Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 26:257–263CrossRefPubMedGoogle Scholar
  82. 82.
    Schlitt HJ, Neipp M, Weimann A et al (1999) Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 17:324–331PubMedGoogle Scholar
  83. 83.
    Shimoda M, Ghobrial RM, Carmody IC et al (2004) Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 10:1478–1486CrossRefPubMedGoogle Scholar
  84. 84.
    Thuluvath PJ, Maheshwari A, Thuluvath NP, Nguyen GC, Segev DL (2009) Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transpl 15:754–762CrossRefPubMedGoogle Scholar
  85. 85.
    Klintmalm GB (1998) Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 228:479–490CrossRefPubMedGoogle Scholar
  86. 86.
    Pawlik TM, Delman KA, Vauthey JN et al (2005) Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11:1086–1092CrossRefPubMedGoogle Scholar
  87. 87.
    Esnaola NF, Lauwers GY, Mirza NQ et al (2002) Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6:224–232CrossRefPubMedGoogle Scholar
  88. 88.
    Busuttil RW, Farmer DG, Yersiz H et al (2005) Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 241:905–918CrossRefPubMedGoogle Scholar
  89. 89.
    Vivarelli M, Bellusci R, Cucchetti A et al (2002) Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74:1746–1751CrossRefPubMedGoogle Scholar
  90. 90.
    Vivarelli M, Cucchetti A, Piscaglia F et al (2005) Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 11:497–503CrossRefPubMedGoogle Scholar
  91. 91.
    Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRefPubMedGoogle Scholar
  92. 92.
    Aloia TA, Goss JA (2009) A report of outcomes after orthotopic liver transplant with allografts from heparin antibody-positive donors. Exp Clin Transplant 7:13–17Google Scholar
  93. 93.
    Guba M, Steinbauer M, Ruhland V et al (2002) Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol Reports 9:981–984Google Scholar
  94. 94.
    Schumacher G, Oidtmann M, Rosewicz S et al (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 34:1392–1393CrossRefPubMedGoogle Scholar
  95. 95.
    Kneteman NM, Oberholzer J, Al Saghier M et al (2004) Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10:1301–1311CrossRefPubMedGoogle Scholar
  96. 96.
    Marsh JW, Finkelstein SD, Demetris AJ et al (2003) Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 9:664–671CrossRefPubMedGoogle Scholar
  97. 97.
    UNOS/OPTN policy 3.6.4.4. http://www.optn.org. Accessed November 2009

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Thomas A. Aloia
    • 1
  • A. Osama Gaber
    • 1
  • R. Mark Ghobrial
    • 1
  1. 1.Department of SurgeryWeill-Cornell Medical College, The Methodist HospitalHoustonUSA

Personalised recommendations